Latest news and press releases about Biohaven Ltd. (BHVN): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that i...
Price
| Price | $12.02 |
| Market Cap | $1.8B |
| Exchange | NYSE |
| Country | US |
Valuation Ratios
| Price / Book | 141.63 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ABCL · CLDX · IMCR · IMNM · NTLA · PHVS · SION
Explore sector: Healthcare · Biotechnology
More sections of BHVN: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks